{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:28:47Z","timestamp":1789129727905,"version":"build-2803163510"},"reference-count":217,"publisher":"Bentham Science Publishers Ltd.","issue":"23","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The Aurora Kinase family (AKI) is composed of serine-threonine protein kinases\ninvolved in the modulation of the cell cycle and mitosis. These kinases are required\nfor regulating the adherence of hereditary-related data. Members of this family can be categorized\ninto aurora kinase A (Ark-A), aurora kinase B (Ark-B), and aurora kinase C\n(Ark-C), consisting of highly conserved threonine protein kinases. These kinases can modulate\ncell processes such as spindle assembly, checkpoint pathway, and cytokinesis during\ncell division. The main aim of this review is to explore recent updates on the oncogenic\nsignaling of aurora kinases in chemosensitive\/chemoresistant cancers and to explore\nthe various medicinal chemistry approaches to target these kinases. We searched\nPubmed, Scopus, NLM, Pubchem, and Relemed to obtain information pertinent to the updated\nsignaling role of aurora kinases and medicinal chemistry approaches and discussed\nthe recently updated roles of each aurora kinases and their downstream signaling cascades\nin the progression of several chemosensitive\/chemoresistant cancers; subsequently,\nwe discussed the natural products (scoulerine, Corynoline, Hesperidin Jadomycin-B, fisetin),\nand synthetic, medicinal chemistry molecules as aurora kinase inhibitors (AKIs). Several\nnatural products' efficacy was explained as AKIs in chemosensitization and chemoresistant\ncancers. For instance, novel triazole molecules have been used against gastric cancer,\nwhereas cyanopyridines are used against colorectal cancer and trifluoroacetate derivatives\ncould be used for esophageal cancer. Furthermore, quinolone hydrazine derivatives\ncan be used to target breast cancer and cervical cancer. In contrast, the indole derivatives\ncan be preferred to target oral cancer whereas thiosemicarbazone-indole could be\nused against prostate cancer, as reported in an earlier investigation against cancerous\ncells. Moreover, these chemical derivatives can be examined as AKIs through preclinical\nstudies. In addition, the synthesis of novel AKIs through these medicinal chemistry substrates\nin the laboratory using in silico and synthetic routes could be beneficial to develop\nprospective novel AKIs to target chemoresistant cancers. This study is beneficial to oncologists,\nchemists, and medicinal chemists to explore novel chemical moiety synthesis\nto target specifically the peptide sequences of aurora kinases in several chemoresistant\ncancer cell types.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867330666230503124408","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T05:13:18Z","timestamp":1683177198000},"page":"3502-3528","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Recent Updates on Oncogenic Signaling of Aurora Kinases in\nChemosensitive, Chemoresistant Cancers: Novel Medicinal Chemistry\nApproaches for Targeting Aurora Kinases"],"prefix":"10.2174","volume":"31","author":[{"given":"Pooja","family":"Kumari","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education\nand Research (JSS AHER), Mysuru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimha Murthy","family":"Beeraka","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education\nand Research (JSS AHER), Mysuru, Karnataka, India"},{"name":"Department of Human Anatomy, I.M. Sechenov\nFirst Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University),\n8\/2 Trubetskaya str., Moscow 119991, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anandkumar","family":"Tengli","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education\nand Research (JSS AHER), Mysuru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurupadayya","family":"Bannimath","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education\nand Research (JSS AHER), Mysuru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramandeep Kaur","family":"Baath","sequence":"additional","affiliation":[{"name":"Department of Pharmaceautics, IFTM University,\nLodhipur Rajput, NH-24 Delhi Road, Moradabad 244102, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayuri","family":"Patil","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education\nand Research (JSS AHER), Mysuru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"Health enews-A news service from Advocate Aurora Health.  Available from:  https:\/\/www.ahchealthenews. com\/(Accessed on: 2021 Jul 8)."},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.4132\/jptm.2016.10.17","volume":"51","author":"Koh H.M.","year":"2017","unstructured":"Koh H.M.; Jang B.G.; Hyun C.L.; Kim Y.S.; Hyun J.W.; Chang W.Y.; Maeng Y.H.; Aurora Kinase A is a prognostic marker in colorectal adenocarcinoma. J Pathol Transl Med  2017,51(1),32-39","journal-title":"J Pathol Transl Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12943-015-0375-4","volume":"14","author":"Katsha A.","year":"2015","unstructured":"Katsha A.; Belkhiri A.; Goff L.; El-Rifai W.; Aurora kinase A in gastrointestinal cancers: Time to target. Mol Cancer  2015,14(1),106","journal-title":"Mol Cancer"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1038\/bjc.2013.608","volume":"109","author":"Goos J.A.C.M.","year":"2013","unstructured":"Goos J.A.C.M.; Coupe V.M.H.; Diosdado B.; Delis-Van Diemen P.M.; Karga C.; Beli\u00ebn J.A.M.; Carvalho B.; van den Tol M.P.; Verheul H.M.W.; Geldof A.A.; Meijer G.A.; Hoekstra O.S.; Fijneman R.J.A.; Aurora kinase A (AURKA) expression in colorectal cancer liver metastasis is associated with poor prognosis. Br J Cancer  2013,109(9),2445-2452","journal-title":"Br J Cancer"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"17978","DOI":"10.1038\/s41598-017-18210-3","volume":"7","author":"Kivinummi K.","year":"2017","unstructured":"Kivinummi K.; Urbanucci A.; Leinonen K.; Tammela T.L.J.; Annala M.; Isaacs W.B.; Bova G.S.; Nykter M.; Visakorpi T.; The expression of AURKA is androgen regulated in castration-resistant prostate cancer. Sci Rep  2017,7(1),17978","journal-title":"Sci Rep"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/1479-5876-9-100","volume":"9","author":"Lo Iacono M.","year":"2011","unstructured":"Lo Iacono M.; Monica V.; Saviozzi S.; Ceppi P.; Bracco E.; Papotti M.; Scagliotti G.V.; Aurora Kinase A expression is associated with lung cancer histological-subtypes and with tumor de-differentiation. J Transl Med  2011,9(1),100","journal-title":"J Transl Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3389\/fonc.2015.00295","volume":"5","author":"D\u2019Assoro A.B.","year":"2016","unstructured":"D\u2019Assoro A.B.; Haddad T.; Galanis E.; Aurora-A Kinase as a promising therapeutic target in cancer. Front Oncol  2016,5(1),295","journal-title":"Front Oncol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"816430","DOI":"10.1155\/2014\/816430","volume":"2014","author":"Baldini E","year":"2014","unstructured":"Baldini E; D\u2019Armiento M; Ulisse S.; A new aurora in anaplastic thyroid cancer therapy. Int J Endocrinol  2014,2014,816430","journal-title":"Int J Endocrinol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"23937","DOI":"10.18632\/oncotarget.14893","volume":"8","author":"Tang A.","year":"2017","unstructured":"Tang A.; Gao K.; Chu L.; Zhang R.; Yang J.; Zheng J.; Aurora kinases: Novel therapy targets in cancers. Oncotarget  2017,8(14),23937-23954","journal-title":"Oncotarget"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2014.14","volume":"34","author":"Goldenson B.","year":"2015","unstructured":"Goldenson B.; Crispino J.D.; The aurora kinases in cell cycle and leukemia. Oncogene  2015,34(5),537-545","journal-title":"Oncogene"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"40714","DOI":"10.1038\/srep40714","volume":"7","author":"Mobley A","year":"2017","unstructured":"Mobley A; Zhang S; Bondaruk J; Wang Y; Majewski T; Caraway NP; Aurora Kinase A is a biomarker for bladder cancer detection and contributes to its aggressive behavior. Sci Rep  2017,7,40714","journal-title":"Sci Rep"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"28436","DOI":"10.1038\/srep28436","volume":"6","author":"Eterno V.","year":"2016","unstructured":"Eterno V.; Zambelli A.; Villani L.; Tuscano A.; Manera S.; Spitaleri A.; Pavesi L.; Amato A.; AURKA controls self-renewal of breast cancer-initiating cells promoting wnt3a stabilization through suppression of miR-128. Sci Rep  2016,6(1),28436","journal-title":"Sci Rep"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13048-016-0238-7","volume":"9","author":"Mignogna C.","year":"2016","unstructured":"Mignogna C.; Staropoli N.; Botta C.; De Marco C.; Rizzuto A.; Morelli M.; Di Cello A.; Franco R.; Camastra C.; Presta I.; Malara N.; Salvino A.; Tassone P.; Tagliaferri P.; Barni T.; Donato G.; Di Vito A.; Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients. J Ovarian Res  2016,9(1),31","journal-title":"J Ovarian Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.molonc.2014.05.012","volume":"8","author":"Katsha A.","year":"2014","unstructured":"Katsha A.; Arras J.; Soutto M.; Belkhiri A.; El-Rifai W.; AURKA regulates JAK2-STAT3 activity in human gastric and esophageal cancers. Mol Oncol  2014,8(8),1419-1428","journal-title":"Mol Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5114\/aoms.2019.91351","volume":"16","author":"Zhang H.","year":"2020","unstructured":"Zhang H.; Bao J.; Zhao S.; Huo Z.; Li B.; MicroRNA-490-3p suppresses hepatocellular carcinoma cell proliferation and migration by targeting the aurora kinase A gene (AURKA). Arch Med Sci  2020,16(2),395-406","journal-title":"Arch Med Sci"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1038\/sj.onc.1209494","volume":"25","author":"Furukawa T.","year":"2006","unstructured":"Furukawa T.; Kanai N.; Shiwaku H.O.; Soga N.; Uehara A.; Horii A.; AURKA is one of the downstream targets of MAPK1\/ERK2 in pancreatic cancer. Oncogene  2006,25(35),4831-4839","journal-title":"Oncogene"},{"key":"ref=17","first-page":"1","volume":"1","year":"2015","unstructured":"Pokuri V.K.; Opyrchal M.; Boland P.M. Aurora Kinase A and gastrointestinal malignancies. Int J Cancer Res Mol Mech  2015,1(3),1-7","journal-title":"Int J Cancer Res Mol Mech"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"180","DOI":"10.4161\/cam.4.2.10715","volume":"4","author":"Yamada M","year":"2010","unstructured":"Yamada M; Hirotsune S; Wynshaw-Boris A; The essential role of LIS1, NDEL1 and Aurora-A in polarity formation and microtubule organization during neurogensis. Cell Adh Migr  2010,4(2),180","journal-title":"Cell Adh Migr"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1158\/1541-7786.MCR-17-0670","volume":"17","author":"Wang F.","year":"2019","unstructured":"Wang F.; Wang L.; Fisher L.A.; Li C.; Wang W.; Peng A.; Phosphatase 1 nuclear targeting subunit (PNUTS) regulates aurora kinases and mitotic progression. Mol Cancer Res  2019,17(1),10-19","journal-title":"Mol Cancer Res"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1083\/jcb.201706103","volume":"217","author":"Huang Y.","year":"2018","unstructured":"Huang Y.; Li T.; Ems-McClung S.C.; Walczak C.E.; Prigent C.; Zhu X.; Zhang X.; Zheng Y.; Aurora A activation in mitosis promoted by BuGZ. J Cell Biol  2018,217(1),107-116","journal-title":"J Cell Biol"},{"key":"ref=21","doi-asserted-by":"publisher","author":"Liu L.","unstructured":"Liu L.; Guo C.; Dammann R.; Tommasi S.; Pfeifer G.P.; RASSF1A interacts with and activates the mitotic kinase Aurora-A.  Oncogenes, 2008, 27(47), 6175-6186.","DOI":"10.1038\/onc.2008.220"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"8625","DOI":"10.1073\/pnas.0402966101","volume":"101","author":"Satinover D.L.","year":"2004","unstructured":"Satinover D.L.; Leach C.A.; Stukenberg P.T.; Brautigan D.L.; Activation of Aurora-A kinase by protein phosphatase inhibitor-2, a bifunctional signaling protein. Proc Natl Acad Sci USA  2004,101(23),8625-8630","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.molcel.2005.08.035","volume":"20","author":"Zhao Z.","year":"2005","unstructured":"Zhao Z.; Lim J.P.; Ng Y.W.; Lim L.; Manser E.; The GIT-associated kinase PAK targets to the centrosome and regulates Aurora-A. Mol Cell  2005,20(2),237-249","journal-title":"Mol Cell"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"28943","DOI":"10.1074\/jbc.M600235200","volume":"281","author":"Shao S.","year":"2006","unstructured":"Shao S.; Wang Y.; Jin S.; Song Y.; Wang X.; Fan W.; Zhao Z.; Fu M.; Tong T.; Dong L.; Fan F.; Xu N.; Zhan Q.; Gadd45a interacts with aurora-A and inhibits its kinase activity. J Biol Chem  2006,281(39),28943-28950","journal-title":"J Biol Chem"},{"key":"ref=25","unstructured":"Interaction and feedback regulation between STK15\/BTAK\/Aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle. Early Detection Research Network  Available from:  https:\/\/edrn.nci.nih.gov\/data-and-resources\/publications\/11551964-interaction-and-feedback-regulation (Accessed on: 2022 Aug 22).","journal-title":"Early Detection Research Network"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1101\/gad.1136004","volume":"18","author":"Sarkissian M.","year":"2004","unstructured":"Sarkissian M.; Mendez R.; Richter J.D.; Progesterone and insulin stimulation of CPEB-dependent polyadenylation is regulated by Aurora A and glycogen synthase kinase-3. Genes Dev  2004,18(1),48","journal-title":"Genes Dev"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1242\/jcs.084970","volume":"124","author":"Johnson E.O.","year":"2011","unstructured":"Johnson E.O.; Chang K.H.; de Pablo Y.; Ghosh S.; Mehta R.; Badve S.; Shah K.; PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. J Cell Sci  2011,124(16),2711-2722","journal-title":"J Cell Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"5566","DOI":"10.1038\/s41467-019-13485-8","volume":"10","author":"Cheng A.","year":"2019","unstructured":"Cheng A.; Zhang P.; Wang B.; Yang D.; Duan X.; Jiang Y.; Xu T.; Jiang Y.; Shi J.; Ding C.; Wu G.; Sang Z.; Wu Q.; Wang H.; Wu M.; Zhang Z.; Pan X.; Pan Y.; Gao P.; Zhang H.; Zhou C.; Guo J.; Yang Z.; Aurora-A mediated phosphorylation of LDHB promotes glycolysis and tumor progression by relieving the substrate-inhibition effect. Nat Commun  2019,10(1),5566","journal-title":"Nat Commun"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"12992","DOI":"10.1074\/jbc.RA118.006937","volume":"294","author":"Mandati V.","year":"2019","unstructured":"Mandati V.; Maestro L.; Del ; Dingli F.; Lombard B.; Loew D.; Molinie N.; Phosphorylation of Merlin by Aurora A kinase appears necessary for mitotic progression. J Biol Chem  2019,294(35),12992","journal-title":"J Biol Chem"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1053\/j.gastro.2018.10.030","volume":"156","author":"Wang-Bishop L.","year":"2019","unstructured":"Wang-Bishop L.; Chen Z.; Gomaa A.; Lockhart A.C.; Salaria S.; Wang J.; Lewis K.B.; Ecsedy J.; Washington K.; Beauchamp R.D.; El-Rifai W.; Inhibition of AURKA reduces proliferation and survival of gastrointestinal cancer cells with activated KRAS by preventing activation of RPS6KB1. Gastroenterology  2019,156(3),662-675.e7","journal-title":"Gastroenterology"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"38960","DOI":"10.1074\/jbc.M111.231498","volume":"286","author":"Shi Y.","year":"2011","unstructured":"Shi Y.; Solomon L.R.; Pereda-Lopez A.; Giranda V.L.; Luo Y.; Johnson E.F.; Shoemaker A.R.; Leverson J.; Liu X.; Ubiquitin-specific cysteine protease 2a (USP2a) regulates the stability of Aurora-A. J Biol Chem  2011,286(45),38960-38968","journal-title":"J Biol Chem"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"111520","DOI":"10.1016\/j.ejmech.2019.07.023","volume":"181","author":"Zhao J.W.","year":"2019","unstructured":"Zhao J.W.; Wu Z.H.; Guo J.W.; Huang M.J.; You Y.Z.; Liu H.M.; Synthesis and anti-gastric cancer activity evaluation of novel triazole nucleobase analogues containing steroidal\/coumarin\/quinoline moieties. Eur J Med Chem  2019,181,111520","journal-title":"Eur J Med Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.2147\/DDDT.S217800","volume":"13","author":"Xu L.","year":"2019","unstructured":"Xu L.; Shi L.; Qiu S.; Chen S.; Lin M.; Xiang Y.; Zhao C.; Zhu J.; Shen L.; Zuo Z.; Design, synthesis, and evaluation of cyanopyridines as anti-colorectal cancer agents via inhibiting STAT3 pathway. Drug Des Devel Ther  2019,13,3369-3381","journal-title":"Drug Des Devel Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"111645","DOI":"10.1016\/j.ejmech.2019.111645","volume":"182","author":"Ke Y.","year":"2019","unstructured":"Ke Y.; Hu T.X.; Huo J.F.; Yan J.K.; Wang J.Y.; Yang R.H.; Xie H.; Liu Y.; Wang N.; Zheng Z.J.; Sun Y.X.; Wang C.; Du J.; Liu H.M.; Synthesis and in vitro biological evaluation of novel derivatives of Flexicaulin A condensation with amino acid trifluoroacetate. Eur J Med Chem  2019,182,111645","journal-title":"Eur J Med Chem"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/molecules21070916","volume":"21","author":"Bingul M.","year":"2016","unstructured":"Bingul M.; Tan O.; Gardner C.; Sutton S.; Arndt G.; Marshall G.; Cheung B.; Kumar N.; Black D.; Synthesis, characterization and anti-cancer activity of hydrazide derivatives incorporating a quinoline moiety. Molecules  2016,21(7),916","journal-title":"Molecules"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ejmech.2019.06.086","volume":"179","author":"Li X.","year":"2019","unstructured":"Li X.; Ding J.; Li N.; Liu W.; Ding F.; Zheng H.; Ning Y.; Wang H.; Liu R.; Ren S.; Synthesis and biological evaluation of celastrol derivatives as anti-ovarian cancer stem cell agents. Eur J Med Chem  2019,179,667-679","journal-title":"Eur J Med Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"112780","DOI":"10.1016\/j.ejmech.2020.112780","volume":"208","author":"Xu Y.","year":"2020","unstructured":"Xu Y.; Zhang X.J.; Li W.B.; Wang X.R.; Wang S.; Qiao X.P.; Chen S.W.; Design, synthesis and biological evaluation of indole-2-one derivatives as potent BRD4 inhibitors. Eur J Med Chem  2020,208,112780","journal-title":"Eur J Med Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1248\/cpb.c17-00035","volume":"66","author":"Li J.","year":"2018","unstructured":"Li J.; Zheng T.; Jin Y.; Xu J.; Yu J.; Lv Y.; Synthesis, molecular docking and biological evaluation of quinolone derivatives as novel anticancer agents. Chem Pharm Bull  2018,66(1),55-60","journal-title":"Chem Pharm Bull"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"112970","DOI":"10.1016\/j.ejmech.2020.112970","volume":"210","author":"He Z.X.","year":"2021","unstructured":"He Z.X.; Huo J.L.; Gong Y.P.; An Q.; Zhang X.; Qiao H.; Yang F.F.; Zhang X.H.; Jiao L.M.; Liu H.M.; Ma L.Y.; Zhao W.; Design, synthesis and biological evaluation of novel thiosemicarbazone-indole derivatives targeting prostate cancer cells. Eur J Med Chem  2021,210,112970","journal-title":"Eur J Med Chem"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1038\/onc.2016.490","volume":"36","author":"Yang N.","year":"2017","unstructured":"Yang N.; Wang C.; Wang Z.; Zona S.; Lin S-X.; Wang X.; Yan M.; Zheng F-M.; Li S-S.; Xu B.; Bella L.; Yong J-S.; Lam E.W-F.; Liu Q.; FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells. Oncogene  2017,36(24),3428-3440","journal-title":"Oncogene"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/carcin\/bgaa118","volume":"42","author":"Tang J.","year":"2021","unstructured":"Tang J.; Yang L.; Li Y.; Ning X.; Chaulagain A.; Wang T.; Wang D.; ARID3A promotes the development of colorectal cancer by upregulating AURKA. Carcinogenesis  2021,42(4),578-586","journal-title":"Carcinogenesis"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"568015","DOI":"10.3389\/fonc.2020.568015","volume":"10","author":"Long Q.","year":"2020","unstructured":"Long Q.; An X.; Chen M.; Wang N.; Sui S.; Li Y.; PUF60\/AURKA axis contributes to tumor progression and malignant phenotypes in bladder cancer. Front Oncol  2020,10,568015","journal-title":"Front Oncol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"10719","DOI":"10.1074\/jbc.M108252200","volume":"277","author":"Tanaka M.","year":"2002","unstructured":"Tanaka M.; Ueda A.; Kanamori H.; Ideguchi H.; Yang J.; Kitajima S.; Ishigatsubo Y.; Cell-cycle-dependent regulation of human aurora A transcription is mediated by periodic repression of E4TF1. J Biol Chem  2002,277(12),10719-10726","journal-title":"J Biol Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"14691","DOI":"10.1074\/jbc.M600163200","volume":"281","author":"Udayakumar T.S.","year":"2006","unstructured":"Udayakumar T.S.; Belakavadi M.; Choi K.H.; Pandey P.K.; Fondell J.D.; Regulation of Aurora-A kinase gene expression via GABP recruitment of TRAP220\/MED1. J Biol Chem  2006,281(21),14691-14699","journal-title":"J Biol Chem"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"4337","DOI":"10.1093\/nar\/gkn417","volume":"36","author":"Hung L.Y.","year":"2008","unstructured":"Hung L.Y.; Tseng J.T.; Lee Y.C.; Xia W.; Wang Y.N.; Wu M.L.; Chuang Y.H.; Lai C.H.; Chang W.C.; Nuclear epidermal growth factor receptor (EGFR) interacts with signal transducer and activator of transcription 5 (STAT5) in activating Aurora-A gene expression. Nucleic Acids Res  2008,36(13),4337-4351","journal-title":"Nucleic Acids Res"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1158\/0008-5472.CAN-12-2397","volume":"73","author":"Chou C.H.","year":"2013","unstructured":"Chou C.H.; Yang N.K.; Liu T.Y.; Tai S.K.; Hsu D.S.S.; Chen Y.W.; Chromosome instability modulated by BMI1-AURKA signaling drives progression in head and neck cancer. Cancer Res  2013,73(2),953-66","journal-title":"Cancer Res"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"e2555","DOI":"10.1038\/cddis.2016.479","volume":"8","author":"Lai C.H.","year":"2017","unstructured":"Lai C.H.; Huang Y.C.; Lee J.C.; Tseng J.T.C.; Chang K.C.; Chen Y.J.; Ding N.J.; Huang P.H.; Chang W.C.; Lin B.W.; Chen R.Y.; Wang Y.C.; Lai Y.C.; Hung L.Y.; Translational upregulation of Aurora-A by hnRNP Q1 contributes to cell proliferation and tumorigenesis in colorectal cancer. Cell Death Dis  2017,8(1),e2555","journal-title":"Cell Death Dis"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1158\/0008-5472.CAN-12-4008","volume":"73","author":"Ice R.J.","year":"2013","unstructured":"Ice R.J.; Mclaughlin S.L.; Livengood R.H.; Culp M.V.; Eddy E.R.; Ivanov A.V.; NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors. Cancer Res  2013,73(10),3168","journal-title":"Cancer Res"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/S0960-9822(03)00166-0","volume":"13","author":"Eyers P.A.","year":"2003","unstructured":"Eyers P.A.; Erikson E.; Chen L.G.; Maller J.L.; A novel mechanism for activation of the protein kinase Aurora A. Curr Biol  2003,13(8),691-697","journal-title":"Curr Biol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1016\/S1097-2765(03)00392-7","volume":"12","author":"Bayliss R.","year":"2003","unstructured":"Bayliss R.; Sardon T.; Vernos I.; Conti E.; Structural basis of Aurora-A activation by TPX2 at the mitotic spindle. Mol Cell  2003,12(4),851-862","journal-title":"Mol Cell"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1242\/jcs.075457","volume":"124","author":"Giubettini M.","year":"2011","unstructured":"Giubettini M.; Asteriti I.A.; Scrofani J.; De Luca M.; Lindon C.; Lavia P.; Guarguaglini G.; Control of Aurora-A stability through interaction with TPX2. J Cell Sci  2011,124(1),113-122","journal-title":"J Cell Sci"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"e19718","DOI":"10.1371\/journal.pone.0019718","volume":"6","author":"Huang Y.H.","year":"2011","unstructured":"Huang Y.H.; Wu C.C.; Chou C.K.; Huang C.Y.F.; A translational regulator, PUM2, promotes both protein stability and kinase activity of Aurora-A. PLoS One  2011,6(5),e19718","journal-title":"PLoS One"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1242\/jcs.092304","volume":"125","author":"Johnson E.O.","year":"2012","unstructured":"Johnson E.O.; Chang K.H.; Ghosh S.; Venkatesh C.; Giger K.; Low P.S.; Shah K.; LIMK2 is a crucial regulator and effector of Aurora-A-kinase-mediated malignancy. J Cell Sci  2012,125(5),1204-1216","journal-title":"J Cell Sci"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"jcs.196790","DOI":"10.1242\/jcs.196790","volume":"130","author":"Wang J.","year":"2017","unstructured":"Wang J.; Nikhil K.; Viccaro K.; Chang L.; Jacobsen M.; Sandusky G.; Shah K.; Aurora A-Twist1 axis promotes highly aggressive phenotypes in pancreatic carcinoma. J Cell Sci  2017,130(6),jcs.196790","journal-title":"J Cell Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/cancers12030660","volume":"12","author":"Nikhil K.","year":"2020","unstructured":"Nikhil K.; Raza A.; Haymour H.S.; Flueckiger B.V.; Chu J.; Shah K.; Aurora kinase A-YBX1 synergy fuels aggressive oncogenic phenotypes and chemoresistance in castration-resistant prostate cancer. Cancers  2020,12(3),660","journal-title":"Cancers"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1083\/jcb.201711070","volume":"217","author":"Woodruff J.B.","year":"2018","unstructured":"Woodruff J.B.; Phase separation of BuGZ promotes Aurora A activation and spindle assembly. J Cell Biol  2018,217(1),9","journal-title":"J Cell Biol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0092-8674(03)00642-1","volume":"114","author":"Hirota T.","year":"2003","unstructured":"Hirota T.; Kunitoku N.; Sasayama T.; Marumoto T.; Zhang D.; Nitta M.; Hatakeyama K.; Saya H.; Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell  2003,114(5),585-598","journal-title":"Cell"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"6177","DOI":"10.1038\/onc.2017.287","volume":"36","author":"Zhong Y.","year":"2017","unstructured":"Zhong Y.; Yang J.; Xu W.W.; Wang Y.; Zheng C-C.; Li B.; He Q-Y.; KCTD12 promotes tumorigenesis by facilitating CDC25B\/CDK1\/Aurora A-dependent G2\/M transition. Oncogene  2017,36(44),6177-6189","journal-title":"Oncogene"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.1038\/s41467-018-05694-4","volume":"9","author":"Wu C.","year":"2018","unstructured":"Wu C.; Lyu J.; Yang E.J.; Liu Y.; Zhang B.; Shim J.S.; Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nat Commun  2018,9(1),3212","journal-title":"Nat Commun"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-017-0483-2","volume":"10","author":"Yu Z.","year":"2017","unstructured":"Yu Z.; Sun Y.; She X.; Wang Z.; Chen S.; Deng Z.; Zhang Y.; Liu Q.; Liu Q.; Zhao C.; Li P.; Liu C.; Feng J.; Fu H.; Li G.; Wu M.; SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA\/B. J Hematol Oncol  2017,10(1),115-115","journal-title":"J Hematol Oncol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1080\/15476286.2020.1804698","volume":"18","author":"Nowak I.","year":"2021","unstructured":"Nowak I.; Boratyn E.; Student S.; Bernhart S.F.; Fallmann J.; Durbas M.; Stadler P.F.; Rokita H.; MCPIP1 ribonuclease can bind and cleave AURKA mRNA in MYCN amplified neuroblastoma cells. RNA Biol  2021,18(1),144-156","journal-title":"RNA Biol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0014-5793(02)02711-4","volume":"519","author":"Taguchi S.","year":"2002","unstructured":"Taguchi S.; Honda K.; Sugiura K.; Yamaguchi A.; Furukawa K.; Urano T.; Degradation of human Aurora-A protein kinase is mediated by hCdh1. FEBS Lett  2002,519(1-3),59-65","journal-title":"FEBS Lett"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1093\/carcin\/bgt225","volume":"34","author":"Park M.T.","year":"2013","unstructured":"Park M.T.; Oh E.T.; Song M.J.; Lee H.; Choi E.K.; Park H.J.; NQO1 prevents radiation-induced aneuploidy by interacting with Aurora-A. Carcinogenesis  2013,34(11),2470-2485","journal-title":"Carcinogenesis"},{"key":"ref=64","unstructured":"SMAD4 suppresses ARK-A-induced metastatic phenotypes via degradation of ARK-Ain a TGFbeta-independent manner.  Available from:  https:\/\/search.yahoo.com\/search?fr=mcafeeandtype=E210US1316G0andp=SMAD4+suppresses+ARK-A-induced+metastatic+phenotypes+via+degradation+of+ARK-Ain+a+TGFbeta-independent+manner(Accessed on: 2022 Aug 22)."},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1158\/0008-5472.CAN-18-0520","volume":"79","author":"Zhang C.","year":"2019","unstructured":"Zhang C.; Qu L.; Lian S.; Meng L.; Min L.; Liu J.; Song Q.; Shen L.; Shou C.; PRL-3 promotes ubiquitination and degradation of AURKA and colorectal cancer progression via dephosphorylation of FZR1. Cancer Res  2019,79(5),928-940","journal-title":"Cancer Res"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"16940","DOI":"10.1073\/pnas.0706493104","volume":"104","author":"Irelan J.T.","year":"2007","unstructured":"Irelan J.T.; Murphy T.J.; DeJesus P.D.; Teo H.; Xu D.; Gomez-Ferreria M.A.; Zhou Y.; Miraglia L.J.; Rines D.R.; Verma I.M.; Sharp D.J.; Tergaonkar V.; Chanda S.K.; A role for I\u03baB kinase 2 in bipolar spindle assembly. Proc Natl Acad Sci USA  2007,104(43),16940-16945","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1038\/sj.onc.1210482","volume":"26","author":"Lim S.K.","year":"2007","unstructured":"Lim S.K.; Gopalan G.; Antizyme1 mediates AURKAIP1-dependent degradation of Aurora-A. Oncogene  2007,26(46),6593-6603","journal-title":"Oncogene"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"45558","DOI":"10.1074\/jbc.M206820200","volume":"277","author":"Kiat L.S.","year":"2002","unstructured":"Kiat L.S.; Hui K.M.; Gopalan G.; Aurora-A kinase interacting protein (AIP), a novel negative regulator of human Aurora-A kinase. J Biol Chem  2002,277(47),45558-45565","journal-title":"J Biol Chem"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3450","DOI":"10.1038\/onc.2016.495","volume":"36","author":"Hasanov E.","year":"2017","unstructured":"Hasanov E.; Chen G.; Chowdhury P.; Weldon J.; Ding Z.; Jonasch E.; Sen S.; Walker C.L.; Dere R.; Ubiquitination and regulation of AURKA identifies a hypoxia-independent E3 ligase activity of VHL. Oncogene  2017,36(24),3450-3463","journal-title":"Oncogene"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1476-4598-11-6","volume":"11","author":"Meehan M.","year":"2012","unstructured":"Meehan M.; Parthasarathi L.; Moran N.; Jefferies C.A.; Foley N.; Lazzari E.; Protein tyrosine phosphatase receptor delta acts as a neuroblastoma tumor suppressor by destabilizing the aurora kinase A oncogene. Mol Cancer  2012,11,6","journal-title":"Mol Cancer"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"6385","DOI":"10.1038\/onc.2008.234","volume":"27","author":"Tong Y.","year":"2008","unstructured":"Tong Y.; Ben-Shlomo A.; Zhou C.; Wawrowsky K.; Melmed S.; Pituitary tumor transforming gene 1 regulates Aurora kinase A activity. Oncogene  2008,27(49),6385-6395","journal-title":"Oncogene"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1534-5807(03)00364-2","volume":"5","author":"Kunitoku N.","year":"2003","unstructured":"Kunitoku N.; Sasayama T.; Marumoto T.; Zhang D.; Honda S.; Kobayashi O.; Hatakeyama K.; Ushio Y.; Saya H.; Hirota T.; CENP-A phosphorylation by Aurora-A in prophase is required for enrichment of Aurora-B at inner centromeres and for kinetochore function. Dev Cell  2003,5(6),853-864","journal-title":"Dev Cell"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/onc.2017.354","volume":"37","author":"Zheng X.","year":"2018","unstructured":"Zheng X.; Chi J.; Zhi J.; Zhang H.; Yue D.; Zhao J.; Li D.; Li Y.; Gao M.; Guo J.; Aurora-A-mediated phosphorylation of LKB1 compromises LKB1\/AMPK signaling axis to facilitate NSCLC growth and migration. Oncogene  2018,37(4),502-511","journal-title":"Oncogene"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1158\/1541-7786.MCR-17-0062","volume":"15","author":"Sarkar S.","year":"2017","unstructured":"Sarkar S.; Brautigan D.L.; Larner J.M.; Aurora kinase A promotes AR degradation via the E3 ligase CHIP. Mol Cancer Res  2017,15(8),1063-1072","journal-title":"Mol Cancer Res"},{"key":"ref=75","first-page":"1265","volume":"2017","author":"Chang S.S.","unstructured":"Chang S.S.; Yamaguchi H.; Xia W.; Lim S.O.; Khotskaya Y.; Wu Y.; Aurora A kinase activates YAP signaling in triple-negative breast cancer. Oncogene  ,2017(9),1265-75","journal-title":"Oncogene"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.1158\/0008-5472.CAN-07-0122","volume":"67","author":"LeRoy P.J.","year":"2007","unstructured":"LeRoy P.J.; Hunter J.J.; Hoar K.M.; Burke K.E.; Shinde V.; Ruan J.; Bowman D.; Galvin K.; Ecsedy J.A.; Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity. Cancer Res  2007,67(11),5362-5370","journal-title":"Cancer Res"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1158\/1078-0432.CCR-13-1187","volume":"20","author":"Sehdev V.","year":"2014","unstructured":"Sehdev V.; Katsha A.; Arras J.; Peng D.; Soutto M.; Ecsedy J.; Zaika A.; Belkhiri A.; El-Rifai W.; HDM2 regulation by AURKA promotes cell survival in gastric cancer. Clin Cancer Res  2014,20(1),76-86","journal-title":"Clin Cancer Res"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.molonc.2014.08.002","volume":"9","author":"Jin S.","year":"2015","unstructured":"Jin S.; Wang X.; Tong T.; Zhang D.; Shi J.; Chen J.; Zhan Q.; Aurora-A enhances malignant development of esophageal squamous cell carcinoma (ESCC) by phosphorylating \u03b2-catenin. Mol Oncol  2015,9(1),249-259","journal-title":"Mol Oncol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1038\/onc.2013.444","volume":"33","author":"Zheng X.Q.","year":"2014","unstructured":"Zheng X.Q.; Guo J.P.; Yang H.; Kanai M.; He L.L.; Li Y.Y.; Koomen J.M.; Minton S.; Gao M.; Ren X.B.; Coppola D.; Cheng J.Q.; Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ER\u03b1 in breast cancer. Oncogene  2014,33(42),4985-4996","journal-title":"Oncogene"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/cdd.2013.93","volume":"20","author":"Moustafa-Kamal M.","year":"2013","unstructured":"Moustafa-Kamal M.; Gamache I.; Lu Y.; Li S.; Teodoro J.G.; BimEL is phosphorylated at mitosis by Aurora A and targeted for degradation by \u03b2TrCP1. Cell Death Differ  2013,20(10),1393-1403","journal-title":"Cell Death Differ"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/onc.2008.434","volume":"28","author":"Dar A.A.","year":"2009","unstructured":"Dar A.A.; Belkhiri A.; El-Rifai W.; The aurora kinase A regulates GSK-3\u03b2 in gastric cancer cells. Oncogene  2009,28(6),866-875","journal-title":"Oncogene"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/nature07185","volume":"455","author":"Mac\u016frek L.","year":"2008","unstructured":"Mac\u016frek L.; Lindqvist A.; Lim D.; Lampson M.A.; Klompmaker R.; Freire R.; Clouin C.; Taylor S.S.; Yaffe M.B.; Medema R.H.; Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature  2008,455(7209),119-123","journal-title":"Nature"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1158\/0008-5472.CAN-06-2272","volume":"67","author":"Briassouli P.","year":"2007","unstructured":"Briassouli P.; Chan F.; Savage K.; Reis-Filho J.S.; Linardopoulos S.; Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res  2007,67(4),1689-1695","journal-title":"Cancer Res"},{"key":"ref=84","volume":"9","author":"Martin B.","year":"2014","unstructured":"Martin B.; Chesnel F.; Delcros J.G.; Jouan F.; Couturier A.; Dugay F.; Correction: Identification of pVHL as a novel substrate for aurora-A in clear cell renal cell carcinoma (ccRCC). PLoS One  2014,9(1)","journal-title":"PLoS One"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1128\/MCB.22.3.874-885.2002","volume":"22","author":"Crosio C.","year":"2002","unstructured":"Crosio C.; Fimia G.M.; Loury R.; Kimura M.; Okano Y.; Zhou H.; Sen S.; Allis C.D.; Sassone-Corsi P.; Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases. Mol Cell Biol  2002,22(3),874-885","journal-title":"Mol Cell Biol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-10935-5","volume":"7","author":"Alexander K.E.","year":"2017","unstructured":"Alexander K.E.; Rizkallah R.; Aurora A phosphorylation of YY1 during mitosis inactivates its DNA binding activity. Sci Reports  2017,7(1),1-13","journal-title":"Sci Reports"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"5405","DOI":"10.1038\/s41388-020-1369-2","volume":"39","author":"Du R.","year":"2020","unstructured":"Du R.; Huang C.; Chen H.; Liu K.; Xiang P.; Yao N.; Yang L.; Zhou L.; Wu Q.; Zheng Y.; Xin M.; Dong Z.; Li X.; SDCBP\/MDA-9\/syntenin phosphorylation by AURKA promotes esophageal squamous cell carcinoma progression through the EGFR-PI3K-Akt signaling pathway. Oncogene  2020,39(31),5405-5419","journal-title":"Oncogene"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1080\/15384101.2016.1192729","volume":"15","author":"Qi D.","year":"2016","unstructured":"Qi D.; Wang Q.; Yu M.; Lan R.; Li S.; Lu F.; Mitotic phosphorylation of SOX2 mediated by Aurora kinase A is critical for the stem-cell like cell maintenance in PA-1 cells. Cell Cycle  2016,15(15),2009-2018","journal-title":"Cell Cycle"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1016\/j.celrep.2016.02.085","volume":"14","author":"Chou E.J.","year":"2016","unstructured":"Chou E.J.; Hung L.Y.; Tang C.J.C.; Hsu W.; Phosphorylation of CPAP by Aurora-A maintains spindle pole integrity during mitosis. Cell Rep  2016,14(12),2975-87","journal-title":"Cell Rep"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"9013","DOI":"10.1074\/jbc.M411068200","volume":"280","author":"Wu J.C.","year":"2005","unstructured":"Wu J.C.; Chen T.Y.; Yu C.T.R.; Tsai S.J.; Hsu J.M.; Tang M.J.; Chou C.K.; Lin W.J.; Yuan C.J.; Huang C.Y.F.; Identification of V23RalA-Ser194 as a critical mediator for Aurora-A-induced cellular motility and transformation by small pool expression screening. J Biol Chem  2005,280(10),9013-9022","journal-title":"J Biol Chem"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1242\/jcs.01108","volume":"117","author":"Dutertre S.","year":"2004","unstructured":"Dutertre S.; Cazales M.; Quaranta M.; Froment C.; Trabut V.; Dozier C.; Mirey G.; Bouch\u00e9 J.P.; Theis-Febvre N.; Schmitt E.; Monsarrat B.; Prigent C.; Ducommun B.; Phosphorylation of CDC25B by Aurora-A at the centrosome contributes to the G2\u2013M transition. J Cell Sci  2004,117(12),2523-2531","journal-title":"J Cell Sci"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1007\/s10637-012-9798-6","volume":"30","author":"Kollareddy M.","year":"2012","unstructured":"Kollareddy M.; Zheleva D.; Dzubak P.; Brahmkshatriya P.S.; Lepsik M.; Hajduch M.; Aurora kinase inhibitors: Progress towards the clinic. Invest New Drugs  2012,30(6),2411-2432","journal-title":"Invest New Drugs"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.devcel.2007.01.019","volume":"12","author":"Portier N.","year":"2007","unstructured":"Portier N.; Audhya A.; Maddox P.S.; Green R.A.; Dammermann A.; Desai A.; Oegema K.; A microtubule-independent role for centrosomes and aurora a in nuclear envelope breakdown. Dev Cell  2007,12(4),515-529","journal-title":"Dev Cell"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1021\/acs.jnatprod.1c00429","volume":"84","year":"2021","unstructured":"The phytochemical scoulerine inhibits aurora kinase activity to induce mitotic and cytokinetic defects. J Nat Prod Li, J.; Yan, Z.; Li, H.; Shi, Q.; Ahire, V.; Zhang, S.; Nimishetti, N.; Yang, D.; Allen, T.D.; Zhang, J 2021,84(8),2312-2320","journal-title":"J Nat Prod"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"112645","DOI":"10.1016\/j.biopha.2022.112645","volume":"147","author":"Yan Z.","year":"2022","unstructured":"Yan Z.; Shi Q.; Liu X.; Li J.; Ahire V.; Zhang S.; The phytochemical, corynoline, diminishes Aurora kinase B activity to induce mitotic defect and polyploidy. Biomed Pharmacother  2022,147,112645","journal-title":"Biomed Pharmacother"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1083\/jcb.200208092","volume":"161","author":"Hauf S.","year":"2003","unstructured":"Hauf S.; Cole R.W.; LaTerra S.; Zimmer C.; Schnapp G.; Walter R.; Heckel A.; van Meel J.; Rieder C.L.; Peters J.M.; The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore\u2013microtubule attachment and in maintaining the spindle assembly checkpoint. J Cell Biol  2003,161(2),281-294","journal-title":"J Cell Biol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1158\/1535-7163.MCT-08-0035","volume":"7","author":"Fu D.H.","year":"2008","unstructured":"Fu D.H.; Jiang W.; Zheng J.T.; Zhao G.Y.; Li Y.; Yi H.; Li Z.R.; Jiang J.D.; Yang K.Q.; Wang Y.; Si S.Y.; Jadomycin B, an Aurora-B kinase inhibitor discovered through virtual screening. Mol Cancer Ther  2008,7(8),2386-2393","journal-title":"Mol Cancer Ther"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/tpj.2008.20","volume":"9","author":"Guo J.","year":"2009","unstructured":"Guo J.; Anderson M.G.; Tapang P.; Palma J.P.; Rodriguez L.E.; Niquette A.; Li J.; Bouska J.J.; Wang G.; Semizarov D.; Albert D.H.; Donawho C.K.; Glaser K.B.; Shah O.J.; Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152. Pharmacogenomics J  2009,9(2),90-102","journal-title":"Pharmacogenomics J"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1002\/jcb.25490","volume":"117","author":"Smith M.L.","year":"2016","unstructured":"Smith M.L.; Murphy K.; Doucette C.D.; Greenshields A.L.; Hoskin D.W.; The dietary flavonoid fisetin causes cell cycle arrest, caspase-dependent apoptosis, and enhanced cytotoxicity of chemotherapeutic drugs in triple-negative breast cancer cells. J Cell Biochem  2016,117(8),1913-1925","journal-title":"J Cell Biochem"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"6571","DOI":"10.3892\/ol.2017.7023","volume":"14","author":"Lee D.","year":"2017","unstructured":"Lee D.; Kim C.; Lim Y.; Shin S.; Aurora kinase A inhibitor TCS7010 demonstrates pro-apoptotic effect through the unfolded protein response pathway in HCT116 colon cancer cells. Oncol Lett  2017,14(6),6571-6577","journal-title":"Oncol Lett"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s12282-018-0914-0","volume":"26","author":"Nakashima K.","year":"2019","unstructured":"Nakashima K.; Uematsu T.; Takahashi K.; Nishimura S.; Tadokoro Y.; Hayashi T.; Sugino T.; Does breast cancer growth rate really depend on tumor subtype? Measurement of tumor doubling time using serial ultrasonography between diagnosis and surgery. Breast Cancer  2019,26(2),206-214","journal-title":"Breast Cancer"},{"key":"ref=102","first-page":"191","volume":"14","author":"Ganjibakhsh M.","year":"2017","unstructured":"Ganjibakhsh M.; Aminishakib P.; Farzaneh P.; Karimi A.; Fazeli S.A.S.; Rajabi M.; Nasimian A.; Naini F.B.; Rahmati H.; Gohari N.S.; Mohebali N.; Asadi M.; Gorji Z.E.; Izadpanah M.; Moghanjoghi S.M.; Ashouri S.; Establishment and characterization of primary cultures from iranian oral squamous cell carcinoma patients by enzymatic method and explant culture. J Dent (Tehran)  2017,14(4),191-202","journal-title":"J Dent (Tehran)"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1039\/C6MD00479B","volume":"8","author":"Ruddarraju R.R.","year":"2017","unstructured":"Ruddarraju R.R.; Murugulla A.C.; Kotla R.; Tirumalasetty M.C.B.; Wudayagiri R.; Donthabakthuni S.; Maroju R.; Design, synthesis, anticancer activity and docking studies of theophylline containing 1,2,3-triazoles with variant amide derivatives. MedChemComm  2017,8(1),176-183","journal-title":"MedChemComm"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"8916729","DOI":"10.1155\/2020\/8916729","volume":"2020","author":"Shan B","year":"2020","unstructured":"Shan B; Zhao R; Zhou J; Zhang M; Qi X; Wang T; AURKA increase the chemosensitivity of colon cancer cells to oxaliplatin by inhibiting the TP53-mediated DNA damage response genes. Biomed Res Int  2020,2020,8916729","journal-title":"Biomed Res Int"},{"key":"ref=105","first-page":"1125","volume":"15","author":"Suman S.","year":"2018","unstructured":"Suman S.; Mishra A.; Network analysis revealed aurora kinase dysregulation in five gynecological types of cancer. Oncol Lett  2018,15(1),1125-1132","journal-title":"Oncol Lett"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ame2.12102","volume":"3","author":"Oliveira R.C.","year":"2020","unstructured":"Oliveira R.C.; Abrantes A.M.; Tralh\u00e3o J.G.; Botelho M.F.; The role of mouse models in colorectal cancer research-The need and the importance of the orthotopic models. Anim Model Exp Med  2020,3(1),1-8","journal-title":"Anim Model Exp Med"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1016\/j.jksus.2020.09.012","volume":"32","author":"Muniyappan G.","year":"2020","unstructured":"Muniyappan G.; Kathavarayan S.; Balachandran C.; Kalliyappan E.; Mahalingam S.M.; Ajees Abdul Salam A.; Aoki S.; Arumugam N.; Almansour A.I.; Suresh Kumar R.; Synthesis, anticancer and molecular docking studies of new class of benzoisoxazolyl-piperidinyl-1, 2, 3-triazoles. J King Saud Univ Sci  2020,32(8),3286-3292","journal-title":"J King Saud Univ Sci"},{"key":"ref=108","first-page":"80","volume":"4","author":"Pandya P.N.","year":"2018","unstructured":"Pandya P.N.; Mankad A.U.; Raval R.M.; Role of aurora kinases in cancer: A comprehensive review.   2018,4(80),80-93"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"112","DOI":"10.4251\/wjgo.v6.i5.112","volume":"6","author":"Napier K.J.","year":"2014","unstructured":"Napier K.J.; Scheerer M.; Misra S.; Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol  2014,6(5),112","journal-title":"World J Gastrointest Oncol"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-020-00323-3","volume":"5","author":"Yang Y-M.","year":"2020","unstructured":"Yang Y-M.; Hong P.; Xu W.W.; He Q-Y.; Li B.; Advances in targeted therapy for esophageal cancer. Signal Transduct Target Ther  2020,5(1),1-11","journal-title":"Signal Transduct Target Ther"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1159\/000164123","volume":"65","author":"Nemoto T.","year":"1997","unstructured":"Nemoto T.; Ohashi K.; Akashi T.; Johnson J.D.; Hirokawa K.; Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology  1997,65(4),195-203","journal-title":"Pathobiology"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1080\/15384101.2016.1215388","volume":"15","author":"J\u00fanior A.P.","year":"2016","unstructured":"J\u00fanior A.P.; Costa N.M.; Da ; Esposito F.; Fusco A.; Pinto L.F.R.; High Mobility Group A proteins in esophageal carcinomas. Cell Cycle  2016,15(18),2410","journal-title":"Cell Cycle"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"305","DOI":"10.3892\/br.2018.1134","volume":"9","author":"He F.","year":"2018","unstructured":"He F.; Ai B.; Tian L.; Identification of genes and pathways in esophageal adenocarcinoma using bioinformatics analysis. Biomed Rep  2018,9(4),305-312","journal-title":"Biomed Rep"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"2968106","DOI":"10.1155\/2016\/2968106","volume":"2016","author":"Su P.","year":"2016","unstructured":"Su P.; Wen S.; Zhang Y.; Li Y.; Xu Y.; Zhu Y.; Identification of the key genes and pathways in esophageal carcinoma. Gastroenterol Res Pract  2016,2016,2968106","journal-title":"Gastroenterol Res Pract"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"782","DOI":"10.4161\/cbt.25362","volume":"14","author":"Clemons N.J.","year":"2013","unstructured":"Clemons N.J.; Phillips W.A.; Lord R.V.; Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther  2013,14(9),782","journal-title":"Cancer Biol Ther"},{"key":"ref=116","first-page":"561","volume":"6","author":"Raufi A.G.","year":"2015","unstructured":"Raufi A.G.; Klempner S.J.; Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations. J Gastrointest Oncol  2015,6(5),561","journal-title":"J Gastrointest Oncol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.jtcvs.2012.10.031","volume":"145","author":"Pennathur A.","year":"2013","unstructured":"Pennathur A.; Xi L.; Litle V.R.; Gooding W.E.; Krasinskas A.; Landreneau R.J.; Gene expression profiles in esophageal adenocarcinoma predict survival after resection. J Thoracic Cardivasc Surg  2013,145(2),505-513","journal-title":"J Thoracic Cardivasc Surg"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1097\/00000658-200008000-00013","volume":"232","author":"Ando N.","year":"2000","unstructured":"Ando N.; Ozawa S.; Kitagawa Y.; Shinozawa Y.; Kitajima M.; Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg  2000,232(2),225-232","journal-title":"Ann Surg"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"5849323","DOI":"10.1155\/2020\/5849323","volume":"2020","author":"Sun S.","year":"2020","unstructured":"Sun S.; Zhang H.; Wang Y.; Gao J.; Zhou S.; Li Y.; Proteomic analysis of human esophageal cancer using tandem mass tag quantifications. Biomed Res Int  2020,2020,5849323","journal-title":"Biomed Res Int"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"3270","DOI":"10.1200\/JCO.1999.17.10.3270","volume":"17","year":"1999","unstructured":"Ilson, D.H.; Saltz, L.; Enzinger, P.; Huang, Y.; Kornblith, A.; Gollub, M.; O'Reilly, E.; Schwartz, G.; DeGroff, J.; Gonzalez, G.; Kelsen, D.P.  Phase II trial of weekly irinotecan plus cisplatin in advanced esophageal cancer. J Clin Oncol  1999,17(10),3270-5","journal-title":"J Clin Oncol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1038\/s41598-017-02623-1","volume":"7","author":"Xia J.L.","year":"2017","unstructured":"Xia J.L.; Fan W.J.; Zheng F.M.; Zhang W.W.; Xie J.J.; Yang M.Y.; Kamran M.; Wang P.; Teng H.M.; Wang C.L.; Liu Q.; Inhibition of AURKA kinase activity suppresses collective invasion in a microfluidic cell culture platform. Sci Rep  2017,7(1),2973","journal-title":"Sci Rep"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1158\/1535-7163.MCT-11-0623","volume":"11","author":"Sehdev V.","year":"2012","unstructured":"Sehdev V.; Peng D.; Soutto M.; Washington M.K.; Revetta F.; Ecsedy J.; The Aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells. Mol Cancer Ther  2012,11(3),763","journal-title":"Mol Cancer Ther"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.2147\/CMAR.S174735","volume":"10","author":"Liao Y.","year":"2018","unstructured":"Liao Y.; Liao Y.; Li J.; Li J.; Fan Y.; Xu B.; Polymorphisms in AURKA and AURKB are associated with the survival of triple-negative breast cancer patients treated with taxane-based adjuvant chemotherapy. Cancer Manag Res  2018,10,3801-3808","journal-title":"Cancer Manag Res"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.breastdis.2013.01.022","volume":"24","author":"Kelly C.M.","year":"2013","unstructured":"Kelly C.M.; A three-gene model to robustly identify breast cancer molecular subtypes.  Breast Dis  2013,24(1),36-38","journal-title":"Breast Dis"},{"key":"ref=125","first-page":"34","volume":"32","author":"Opyrchal M.","year":"2015","unstructured":"Opyrchal M.; Divya K.; Sangameswaran G.; Khoury T.; Aurora kinase inhibitors in breast cancer treatment. Cancer  2015,32,34","journal-title":"Cancer"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"e18042","DOI":"10.1097\/MD.0000000000018042","volume":"98","author":"Zhao C.H.","year":"2019","unstructured":"Zhao C.H.; Qu L.; Zhang H.; Qu R.; Identification of breast cancer-related circRNAs by analysis of microarray and RNA-sequencing data. Medicine  2019,98(46),e18042","journal-title":"Medicine"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"e81035","DOI":"10.1371\/journal.pone.0081035","volume":"8","author":"Engin H.B.","year":"2013","unstructured":"Engin H.B.; Guney E.; Keskin O.; Oliva B.; Gursoy A.; ntegrating structure to protein-protein interaction networks that drive metastasis to brain and lung in breast cancer. PLoS One  2013,8(11),e81035","journal-title":"PLoS One"},{"key":"ref=128","author":"Lassmann S.","year":"2007","unstructured":"Lassmann S.; Shen Y.; Wiehle P.; Walch A.; Gitsch G.; Predictive Value of Aurora-A\/STK15 Expression for Late Stage Epithelial Ovarian Cancer Patients Treated by Adjuvant Chemotherapy.   Available from:  www.aacrjournals.org2007"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"4036","DOI":"10.1038\/onc.2015.472","volume":"35","author":"Duckworth C.","year":"2016","unstructured":"Duckworth C.; Zhang L.; Carroll S.L.; Ethier S.P.; Cheung H.W.; Overexpression of GAB2 in ovarian cancer cells promotes tumor growth and angiogenesis by upregulating chemokine expression. Oncogene  2016,35(31),4036-4047","journal-title":"Oncogene"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.3892\/ijo.2015.2971","volume":"46","author":"Liu X.","year":"2015","unstructured":"Liu X.; Gao Y.; Zhao B.; Li X.; Lu Y.; Zhang J.; Li D.; Li L.; Yin F.; Discovery of microarray-identified genes associated with ovarian cancer progression. Int J Oncol  2015,46(6),2467-2478","journal-title":"Int J Oncol"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s13048-018-0467-z","volume":"11","author":"Li W.","year":"2018","unstructured":"Li W.; Liu Z.; Liang B.; Chen S.; Zhang X.; Tong X.; Lou W.; Le L.; Tang X.; Fu F.; Identification of core genes in ovarian cancer by an integrative meta-analysis. J Ovarian Res  2018,11(1),94","journal-title":"J Ovarian Res"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"Thorn C.F.","year":"2011","unstructured":"Thorn C.F.; Oshiro C.; Marsh S.; Hernandez-Boussard T.; Mcleod H.; Klein T.E.; Doxorubicin pathways: Pharmacodynamics and adverse effects. Pharmacogenet Genomics  2011,21(7),440","journal-title":"Pharmacogenet Genomics"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12943-020-01163-z","volume":"19","author":"Gan X.","year":"2020","unstructured":"Gan X.; Zhu H.; Jiang X.; Obiegbusi S.C.; Yong M.; Long X.; Hu J.; CircMUC16 promotes autophagy of epithelial ovarian cancer via interaction with ATG13 and miR-199a. Mol Cancer  2020,19(1),45","journal-title":"Mol Cancer"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1097\/GRF.0000000000000312","volume":"60","author":"Karnezis A.N.","year":"2017","unstructured":"Karnezis A.N.; Cho K.R.; Preclinical models of ovarian cancer: pathogenesis, problems, and implications for prevention. Clinical Obstetrics and Gynecology  Available from:  https:\/\/journals.lww.com\/00003081- 201712000-000112017,60,789-800","journal-title":"Clinical Obstetrics and Gynecology"},{"key":"ref=135","author":"Alcaraz-Sanabria A.","year":"2017","unstructured":"Alcaraz-Sanabria A.; Nieto-Jim Enez C.; Cancer biology and translational studies synthetic lethality interaction between aurora kinases and chek1 inhibitors in ovarian cancer.  Available from:  https:\/\/www.oncomine.org\/resource\/ (Accessed on: 2021 Mar 13)2017"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"10272","DOI":"10.1021\/jm300850v","volume":"55","author":"Carosati E.","year":"2012","unstructured":"Carosati E.; Tochowicz A.; Marverti G.; Guaitoli G.; Benedetti P.; Ferrari S.; Stroud R.M.; Finer-Moore J.; Luciani R.; Farina D.; Cruciani G.; Costi M.P.; Inhibitor of ovarian cancer cells growth by virtual screening: a new thiazole derivative targeting human thymidylate synthase. J Med Chem  2012,55(22),10272-10276","journal-title":"J Med Chem"},{"key":"ref=137","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1016\/j.bmcl.2016.05.017","volume":"26","author":"An Y.","year":"2016","unstructured":"An Y.; Lee E.; Yu Y.; Yun J.; Lee M.Y.; Kang J.S.; Design and synthesis of novel benzoxazole analogs as Aurora B kinase inhibitors. Bioorganic Med Chem Lett  2016,26(13),3067-72","journal-title":"Bioorganic Med Chem Lett"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"9122","DOI":"10.1021\/jm401115g","volume":"56","author":"Bavetsias V.","year":"2013","unstructured":"Bavetsias V.; Faisal A.; Crumpler S.; Brown N.; Kosmopoulou M.; Joshi A.; Atrash B.; P\u00e9rez-Fuertes Y.; Schmitt J.A.; Boxall K.J.; Burke R.; Sun C.; Avery S.; Bush K.; Henley A.; Raynaud F.I.; Workman P.; Bayliss R.; Linardopoulos S.; Blagg J.; Aurora isoform selectivity: design and synthesis of imidazo[4,5-b]pyridine derivatives as highly selective inhibitors of Aurora-A kinase in cells. J Med Chem  2013,56(22),9122-9135","journal-title":"J Med Chem"},{"key":"ref=139","unstructured":"Protein-protein interaction spider of oral cancer.  Available from:  https:\/\/figshare.com\/articles\/figure\/Protein-protein_interaction_spider_of_oral_cancer\/6396827 (Accessed on: 2021 Mar 16)"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s00428-006-0360-9","volume":"450","year":"2021","unstructured":"Qi, G.; Ogawa, I.; Kudo, Y.; Miyauchi, M.; Siriwardena, B.S.M.S.; Shimamoto, F.; Tatsuka, M.; Takata, T.  Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Archiv  2021,450(3),297-302","journal-title":"Virchows Archiv"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1080\/15384101.2019.1642680","volume":"18","author":"Wenzhao L.","year":"2019","unstructured":"Wenzhao L.; Jiangdong N.; Deye S.; Muliang D.; Junjie W.; Xianzhe H.; Mingming Y.; Jun H.; Dual regulatory roles of HMGB1 in inflammatory reaction of chondrocyte cells and mice. Cell Cycle  2019,18(18),2268-2280","journal-title":"Cell Cycle"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3389\/fonc.2018.00398","volume":"8","author":"Wang Y.F.","year":"2018","unstructured":"Wang Y.F.; Li B.W.; Sun S.; Li X.; Su W.; Wang Z.H.; Circular RNA expression in oral squamous cell carcinoma. Front Oncol  2018,8,398","journal-title":"Front Oncol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1186\/s12885-019-5939-z","volume":"19","author":"Christowitz C.","year":"2019","unstructured":"Christowitz C.; Davis T.; Isaacs A.; van Niekerk G.; Hattingh S.; Engelbrecht A.M.; Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer  2019,19(1),757","journal-title":"BMC Cancer"},{"key":"ref=144","first-page":"65","volume":"10","author":"Saxena V.L.","year":"2010","unstructured":"Saxena V.L.; Gupta S.; Srivastava S.; Study of ligand based virtual screening tools in computer aided drug designing for oral cancer. IOSR J Pharm Biol Sci  2010,10,65-74","journal-title":"IOSR J Pharm Biol Sci"},{"key":"ref=145","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fonc.2015.00278","volume":"5","author":"Bavetsias V.","year":"2015","unstructured":"Bavetsias V.; Linardopoulos S.; Aurora kinase inhibitors: Current status and outlook. Front Oncol  2015,5,278","journal-title":"Front Oncol"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejogrb.2008.09.012","volume":"142","author":"Twu N.F.","year":"2009","unstructured":"Twu N.F.; Yuan C.C.; Yen M.S.; Lai C.R.; Chao K.C.; Wang P.H.; Wu H.H.; Chen Y.J.; Expression of Aurora kinase A and B in normal and malignant cervical tissue: High Aurora A kinase expression in squamous cervical cancer. Eur J Obstet Gynecol Reprod Biol  2009,142(1),57-63","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref=147","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"Dasari S.","year":"2014","unstructured":"Dasari S.; Bernard Tchounwou P.; Cisplatin in cancer therapy: Molecular mechanisms of action. Eur J Pharmacol  2014,740,364-78","journal-title":"Eur J Pharmacol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"8959210","DOI":"10.1155\/2020\/8959210","volume":"2020","author":"Wei J","year":"2020","unstructured":"Wei J; Wang Y; Shi K; Wang Y.; Identification of core prognosis-related candidate genes in cervical cancer via integrated bioinformatical analysis. Biomed Res Int  2020,2020,8959210","journal-title":"Biomed Res Int"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1158\/1535-7163.MCT-17-0159","volume":"16","author":"Martin D.","year":"2017","unstructured":"Martin D.; Fallaha S.; Proctor M.; Stevenson A.; Perrin L.; McMillan N.; Gabrielli B.; Inhibition of Aurora A and Aurora B is required for the sensitivity of HPV-driven cervical cancers to Aurora kinase inhibitors. Mol Cancer Ther  2017,16(9),1934-1941","journal-title":"Mol Cancer Ther"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2217\/fmb-2019-0242","volume":"15","author":"Khan A.A.","year":"2020","unstructured":"Khan A.A.; A Abuderman A.; Ashraf M.T.; Khan Z.; Protein\u2013protein interactions of HPV-Chlamydia trachomatis human and their potential in cervical cancer. Future Microbiol  2020,15(7),509-520","journal-title":"Future Microbiol"},{"key":"ref=151","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.gore.2018.06.007","volume":"25","author":"Ager B.J.","year":"2018","unstructured":"Ager B.J.; Gallardo-Rinc\u00f3n D.; de Le\u00f3n D.C.; Ch\u00e1vez-Blanco A.; Chuang L.; Due\u00f1as-Gonz\u00e1lez A.; Advancing clinical research globally: Cervical cancer research network from Mexico. Gynecol Oncol Rep  2018,25,90-3","journal-title":"Gynecol Oncol Rep"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/IGC.0000000000000587","author":"Sagae S.","year":"2016","unstructured":"Sagae S.; Monk B.J.; Pujade-Lauraine E.; Gaffney D.K.; Narayan K.; Ryu S.Y.; Advances and concepts in cervical cancer trials: A road map for the future. Int J Gynecol Cancer  2016,199-207","journal-title":"Int J Gynecol Cancer"},{"key":"ref=153","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.molstruc.2019.04.023","volume":"1189","author":"Kumar A.","year":"2019","unstructured":"Kumar A.; Rathi E.; Kini S.G.; E-pharmacophore modelling, virtual screening, molecular dynamics simulations and in-silico ADME analysis for identification of potential E6 inhibitors against cervical cancer. J Mol Struct  2019,1189,299-306","journal-title":"J Mol Struct"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1155\/2014\/842037","volume":"2014","author":"Bengtsson E.","year":"2014","unstructured":"Bengtsson E.; Malm P.; Screening for cervical cancer using automated analysis of PAP-smears. Comput Math Methods Med  2014,2014,2037","journal-title":"Comput Math Methods Med"},{"key":"ref=155","unstructured":"How Long Does it Take for Cervical Cancer to Develop?- Moffitt.  Available from:  https:\/\/moffitt.org\/cancers\/cervical-cancer\/faqs\/how-long-does-it-take-for-cervical-cancer- to-develop\/ (Accessed on: 2021 Mar 19)."},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.3390\/molecules26071981","volume":"26","author":"Borah N.A.","year":"2021","unstructured":"Borah N.A.; Reddy M.M.; Aurora kinase B inhibition: A potential therapeutic strategy for cancer. Molecules  2021,26(7),1981","journal-title":"Molecules"},{"key":"ref=157","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.1016\/j.bmc.2014.09.029","volume":"22","author":"Cai J.","year":"2014","unstructured":"Cai J.; Li L.; Hong K.H.; Wu X.; Chen J.; Wang P.; Discovery of 4-aminoquinazoline-urea derivatives as Aurora kinase inhibitors with antiproliferative activity. Bioorganic Med Chem  2014,22(21),5813-23","journal-title":"Bioorganic Med Chem"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"3444","DOI":"10.1002\/slct.202004666","volume":"6","author":"Chate A.V.","year":"2021","unstructured":"Chate A.V.; Tagad P.A.; Bondle G.M.; Sarkate A.P.; Tiwari S.V.; Azad R.; Design, synthesis and biological evaluation of tetrahydrodibenzo[b,g][1,8]napthyridinones as potential anticancer agents and novel aurora kinases inhibitors. ChemistrySelect  2021,6(14),3444-3452","journal-title":"ChemistrySelect"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s12325-018-0766-1","volume":"35","author":"Merriel S.W.D.","year":"2018","unstructured":"Merriel S.W.D.; Funston G.; Hamilton W.; Prostate cancer in primary care. Adv Ther  2018,35,1285-94","journal-title":"Adv Ther"},{"key":"ref=160","unstructured":"Prostate cancer: Symptoms, treatment, and causes  Available from:  https:\/\/www.medicalnewstoday.com\/articles\/150086#symptoms(Accessed on: 2021 Mar 22)"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/onc.2010.468","volume":"30","author":"Wang B.","year":"2011","unstructured":"Wang B.; Hasan M.K.; Alvarado E.; Yuan H.; Wu H.; Chen W.Y.; NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene  2011,30(8),907-921","journal-title":"Oncogene"},{"key":"ref=162","unstructured":"Why Are Prostate Cancer Preclinical Models Hard to Develop?  Available from:  https:\/\/blog.crownbio.com\/prostate-cancer-preclinical-models(Accessed on: 2021 Mar 21)"},{"key":"ref=163","doi-asserted-by":"publisher","first-page":"105145","DOI":"10.1016\/j.phrs.2020.105145","volume":"161","author":"Matos B.","year":"2020","unstructured":"Matos B.; Howl J.; Jer\u00f3nimo C.; Fardilha M.; The disruption of protein-protein interactions as a therapeutic strategy for prostate cancer. Pharmacological Research. Academic Press  Available from:  https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820314535(Accessed on: 2021 Mar 21).2020,161,105145"},{"key":"ref=164","unstructured":"High-Fat Diet Linked to Prostate Cancer Metastasis - National Cancer Institute.   Available from:  https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2018\/high- fat-diet-prostate-metastasis(Accessed on: 2021 Mar 21)."},{"key":"ref=165","doi-asserted-by":"publisher","first-page":"12216","DOI":"10.1073\/pnas.97.22.12216","volume":"97","author":"Srikantan V.","year":"2000","unstructured":"Srikantan V.; Zou Z.; Petrovics G.; Xu L.; Augustus M.; Davis L.; PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc Natl Acad Sci  2000,97(22),12216-21","journal-title":"Proc Natl Acad Sci"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.molmet.2017.11.013","volume":"8","author":"Lutz S.Z.","year":"2018","unstructured":"Lutz S.Z.; Hennenlotter J.; Scharpf M.O.; Sailer C.; Fritsche L.; Schmid V.; Kantartzis K.; Wagner R.; Lehmann R.; Berti L.; Peter A.; Staiger H.; Fritsche A.; Fend F.; Todenh\u00f6fer T.; Stenzl A.; H\u00e4ring H.U.; Heni M.; Androgen receptor overexpression in prostate cancer in type 2 diabetes. Mol Metab  2018,8,158-166","journal-title":"Mol Metab"},{"key":"ref=167","volume":"7","author":"Arjun H.A.","year":"2019","unstructured":"Arjun H.A.; Elancheran R.; Manikandan N.; Lakshmithendral K.; Ramanathan M.; Bhattacharjee A.; Design, synthesis, and biological evaluation of (E)-N\u2019-((1-Chloro-3,4-Dihydronaphthalen-2-yl)Methylene)benzohydrazide derivatives as anti-prostate cancer agents. Front Chem  2019,7-474","journal-title":"Front Chem"},{"key":"ref=168","first-page":"15030","volume":"8","author":"Zhang Y.","year":"2015","unstructured":"Zhang Y.; Xu Q.; Liu G.; Huang H.; Lin W.; Huang Y.; Effect of histone deacetylase on prostate carcinoma. Int J Clin Exp Pathol  2015,8(11),15030","journal-title":"Int J Clin Exp Pathol"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"5271","DOI":"10.1158\/1078-0432.CCR-03-0709","volume":"10","author":"Park J.H.","year":"2004","unstructured":"Park J.H.; Jung Y.; Kim T.Y.; Kim S.G.; Jong H.S.; Lee J.W.; Kim D.K.; Lee J.S.; Kim N.K.; Kim T.Y.; Bang Y.J.; Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res  2004,10(15),5271-5281","journal-title":"Clin Cancer Res"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-08-0721","volume":"14","author":"Fiskus W.","year":"2008","unstructured":"Fiskus W.; Wang Y.; Joshi R.; Rao R.; Yang Y.; Chen J.; Kolhe R.; Balusu R.; Eaton K.; Lee P.; Ustun C.; Jillella A.; Buser C.A.; Peiper S.; Bhalla K.; Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin Cancer Res  2008,14(19),6106-6115","journal-title":"Clin Cancer Res"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1182\/blood-2008-05-159392","volume":"112","author":"Dai Y.","year":"2008","unstructured":"Dai Y.; Chen S.; Pei X.Y.; Almenara J.A.; Kramer L.B.; Venditti C.A.; Dent P.; Grant S.; Interruption of the Ras\/MEK\/ERK signaling cascade enhances Chk1 inhibitor\u2013induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood  2008,112(6),2439-2449","journal-title":"Blood"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s10549-012-2171-9","volume":"135","author":"Fiskus W.","year":"2012","unstructured":"Fiskus W.; Hembruff S.L.; Rao R.; Sharma P.; Balusu R.; Venkannagari S.; Smith J.E.; Peth K.; Peiper S.C.; Bhalla K.N.; Co-treatment with vorinostat synergistically enhances activity of Aurora kinase inhibitor against human breast cancer cells. Breast Cancer Res Treat  2012,135(2),433-444","journal-title":"Breast Cancer Res Treat"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1158\/0008-5472.CAN-10-2259","volume":"71","author":"Kretzner L.","year":"2011","unstructured":"Kretzner L.; Scuto A.; Dino P.M.; Kowolik C.M.; Wu J.; Ventura P.; Jove R.; Forman S.J.; Yen Y.; Kirschbaum M.H.; Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels. Cancer Res  2011,71(11),3912-3920","journal-title":"Cancer Res"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1158\/1078-0432.CCR-15-0033","volume":"21","author":"Zullo K.M.","year":"2015","unstructured":"Zullo K.M.; Guo Y.; Cooke L.; Jirau-Serrano X.; Mangone M.; Scotto L.; Amengual J.E.; Mao Y.; Nandakumar R.; Cremers S.; Duong J.; Mahadevan D.; O\u2019Connor O.A.; Aurora A kinase inhibition selectively synergizes with histone deacetylase inhibitor through cytokinesis failure in T-cell lymphoma. Clin Cancer Res  2015,21(18),4097-4109","journal-title":"Clin Cancer Res"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/cam4.289","volume":"3","author":"Paller C.J.","year":"2014","unstructured":"Paller C.J.; Wissing M.D.; Mendonca J.; Sharma A.; Kim E.; Kim H.S.; Kortenhorst M.S.Q.; Gerber S.; Rosen M.; Shaikh F.; Zahurak M.L.; Rudek M.A.; Hammers H.; Rudin C.M.; Carducci M.A.; Kachhap S.K.; Combining the pan-aurora kinase inhibitor  900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med  2014,3(5),1322-1335","journal-title":"Cancer Med"},{"key":"ref=176","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41591-018-0264-7","volume":"25","author":"Shah K.N.","year":"2019","unstructured":"Shah K.N.; Bhatt R.; Rotow J.; Rohrberg J.; Olivas V.; Wang V.E.; Hemmati G.; Martins M.M.; Maynard A.; Kuhn J.; Galeas J.; Donnella H.J.; Kaushik S.; Ku A.; Dumont S.; Krings G.; Haringsma H.J.; Robillard L.; Simmons A.D.; Harding T.C.; McCormick F.; Goga A.; Blakely C.M.; Bivona T.G.; Bandyopadhyay S.; Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer. Nat Med  2019,25(1),111-118","journal-title":"Nat Med"},{"key":"ref=177","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/s41419-019-2120-1","volume":"10","author":"\u010can\u010der M.","year":"2019","unstructured":"\u010can\u010der M.; Drews L.F.; Bengtsson J.; Bolin S.; Ros\u00e9n G.; Westermark B.; Nelander S.; Forsberg-Nilsson K.; Uhrbom L.; Weishaupt H.; Swartling F.J.; BET and Aurora Kinase A inhibitors synergize against MYCN-positive human glioblastoma cells. Cell Death Dis  2019,10(12),881","journal-title":"Cell Death Dis"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.neo.2018.08.002","volume":"20","author":"Felgenhauer J.","year":"2018","unstructured":"Felgenhauer J.; Tomino L.; Selich-Anderson J.; Bopp E.; Shah N.; Dual BRD4 and AURKA inhibition is synergistic against MYCN-amplified and nonamplified neuroblastoma. Neoplasia  2018,20(10),965-974","journal-title":"Neoplasia"},{"key":"ref=179","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1158\/0008-5472.CAN-14-2405","volume":"75","author":"Vilgelm A.E.","year":"2015","unstructured":"Vilgelm A.E.; Pawlikowski J.S.; Liu Y.; Hawkins O.E.; Davis T.A.; Smith J.; Weller K.P.; Horton L.W.; McClain C.M.; Ayers G.D.; Turner D.C.; Essaka D.C.; Stewart C.F.; Sosman J.A.; Kelley M.C.; Ecsedy J.A.; Johnston J.N.; Richmond A.; Mdm2 and aurora kinase A inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells. Cancer Res  2015,75(1),181-193","journal-title":"Cancer Res"},{"key":"ref=180","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1182\/blood-2008-01-128611","volume":"112","author":"Kojima K.","year":"2008","unstructured":"Kojima K.; Konopleva M.; Tsao T.; Nakakuma H.; Andreeff M.; Concomitant inhibition of Mdm2-p53 interaction and Aurora kinases activates the p53-dependent postmitotic checkpoints and synergistically induces p53-mediated mitochondrial apoptosis along with reduced endoreduplication in acute myelogenous leukemia. Blood  2008,112(7),2886-2895","journal-title":"Blood"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/onc.2011.314","volume":"31","author":"Ratushny V.","year":"2012","unstructured":"Ratushny V.; Pathak H.B.; Beeharry N.; Tikhmyanova N.; Xiao F.; Li T.; Dual inhibition of SRC and Aurora kinases induces postmitotic attachment defects and cell death. Oncogene  2012,31(10),1217-27","journal-title":"Oncogene"},{"key":"ref=182","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1158\/1535-7163.MCT-17-0223","volume":"16","author":"Alcaraz-Sanabria A.","year":"2017","unstructured":"Alcaraz-Sanabria A.; Nieto-Jimenez C.; Corrales- Sanchez V.; Serrano-Oviedo L.; Andres-Pretel F.; Montero J.C.; Synthetic lethality interaction between aurora kinases and CHEK1 inhibitors in ovarian cancer. Mol Cancer Ther  2017,16(11),2552-2562","journal-title":"Mol Cancer Ther"},{"key":"ref=183","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12967-016-1012-8","volume":"14","author":"Lu Y.","year":"2016","unstructured":"Lu Y.; Liu L.L.; Liu S.S.; Fang Z.G.; Zou Y.; Deng X.; Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells. J Transl Med  2016,14(1),270","journal-title":"J Transl Med"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1158\/1078-0432.CCR-12-0436","volume":"18","author":"Brewer Savannah K.J.","year":"2012","unstructured":"Brewer Savannah K.J.; Demicco E.G.; Lusby K.; Ghadimi M.P.H.; Belousov R.; Young E.; Zhang Y.; Huang K.L.; Lazar A.J.; Hunt K.K.; Pollock R.E.; Creighton C.J.; Anderson M.L.; Lev D.; Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res  2012,18(17),4633-4645","journal-title":"Clin Cancer Res"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"3430","DOI":"10.1158\/1078-0432.CCR-18-0440","volume":"25","author":"Lee J.W.","year":"2019","unstructured":"Lee J.W.; Parameswaran J.; Sandoval-Schaefer T.; Eoh K.J.; Yang D.; Zhu F.; Mehra R.; Sharma R.; Gaffney S.G.; Perry E.B.; Townsend J.P.; Serebriiskii I.G.; Golemis E.A.; Issaeva N.; Yarbrough W.G.; Koo J.S.; Burtness B.; Combined Aurora Kinase A (AURKA) and WEE1 inhibition demonstrates synergistic antitumor effect in squamous cell carcinoma of the head and neck. Clin Cancer Res  2019,25(11),3430-3442","journal-title":"Clin Cancer Res"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1021\/acschemneuro.6b00251","volume":"8","author":"Daniele S.","year":"2017","unstructured":"Daniele S.; Sestito S.; Pietrobono D.; Giacomelli C.; Chiellini G.; Di Maio D.; Dual inhibition of PDK1 and aurora kinase A: An effective strategy to induce differentiation and apoptosis of human glioblastoma multiforme stem cells. ACS Chem Neurosci  2017,8(1),100-114","journal-title":"ACS Chem Neurosci"},{"key":"ref=187","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.3390\/cancers11111695","volume":"11","author":"Casari I.","year":"2019","unstructured":"Casari I.; Domenichini A.; Sestito S.; Capone E.; Sala G.; Rapposelli S.; Falasca M.; Dual PDK1\/Aurora kinase A inhibitors reduce pancreatic cancer cell proliferation and colony formation. Cancers  2019,11(11),1695","journal-title":"Cancers"},{"key":"ref=188","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12967-014-0216-z","volume":"12","author":"Caputo E.","year":"2014","unstructured":"Caputo E.; Miceli R.; Motti M.L.; Tat\u00e9 R.; Fratangelo F.; Botti G.; Mozzillo N.; Carriero M.V.; Cavalcanti E.; Palmieri G.; Ciliberto G.; Pirozzi G.; Ascierto P.A.; AurkA inhibitors enhance the effects of B-RAF and MEK inhibitors in melanoma treatment. J Transl Med  2014,12(1),216","journal-title":"J Transl Med"},{"key":"ref=189","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.canlet.2013.08.018","volume":"341","author":"Horwacik I.","year":"2013","unstructured":"Horwacik I.; Durbas M.; Boratyn E.; W\u0119grzyn P.; Rokita H.; Targeting GD2 ganglioside and aurora A kinase as a dual strategy leading to cell death in cultures of human neuroblastoma cells. Cancer Lett  2013,341(2),248-264","journal-title":"Cancer Lett"},{"key":"ref=190","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10495-018-1472-9","volume":"23","author":"Durbas M.","year":"2018","unstructured":"Durbas M.; Pabisz P.; Wawak K.; Wi\u015bniewska A.; Boratyn E.; Nowak I.; Horwacik I.; Wo\u017anicka O.; Rokita H.; GD2 ganglioside-binding antibody 14G2a and specific aurora A kinase inhibitor MK-5108 induce autophagy in IMR-32 neuroblastoma cells. Apoptosis  2018,23(9-10),492-511","journal-title":"Apoptosis"},{"key":"ref=191","doi-asserted-by":"publisher","first-page":"5338","DOI":"10.1158\/1078-0432.CCR-15-0293","volume":"21","author":"Liu Y.","year":"2015","unstructured":"Liu Y.; Hawkins O.E.; Vilgelm A.E.; Pawlikowski J.S.; Ecsedy J.A.; Sosman J.A.; Kelley M.C.; Richmond A.; Combining an aurora kinase inhibitor and a death receptor ligand\/agonist antibody triggers apoptosis in melanoma cells and prevents tumor growth in preclinical mouse models. Clin Cancer Res  2015,21(23),5338-5348","journal-title":"Clin Cancer Res"},{"key":"ref=192","unstructured":"Aurora A Inhibition Eliminates Myeloid Cell-Mediated Immunosuppression and Enhances the Efficacy of Anti-PD-L1 Therapy in Breast Cancer.   Available from:  https:\/\/europepmc.org\/article\/MED\/30902796 (Accessed on: 2022 Sep 28)."},{"key":"ref=193","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s12943-020-01305-3","volume":"20","author":"Du R.","year":"2021","unstructured":"Du R.; Huang C.; Liu K.; Li X.; Dong Z.; Targeting AURKA in Cancer: Molecular mechanisms and opportunities for cancer therapy. Mol Cancer  2021,20(1),15","journal-title":"Mol Cancer"},{"key":"ref=194","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1016\/j.bmcl.2014.06.078","volume":"4","author":"Defaux J.","year":"2014","unstructured":"Defaux J.; Antoine M.; Log\u00e9 C.; Le Borgne M.; Schuster T.; Seipelt I.; Discovery of (7-aryl-1,5-naphthyridin-2-yl)ureas as dual inhibitors of ERK2 and Aurora B kinases with antiproliferative activity against cancer cells. Bioorganic Med Chem Lett  2014,4(16),3748-52","journal-title":"Bioorganic Med Chem Lett"},{"key":"ref=195","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ejmech.2013.04.058","volume":"65","author":"Li J.","year":"2013","unstructured":"Li J.; Hu H.; Lang Q.; Zhang H.; Huang Q.; Wu Y.; Yu L.; A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via    inhibiting Aurora B kinase activity. Eur J Med Chem  2013,65,151-157","journal-title":"Eur J Med Chem"},{"key":"ref=196","doi-asserted-by":"publisher","first-page":"113495","DOI":"10.1016\/j.ejmech.2021.113495","volume":"221","author":"Pradhan T.","year":"2021","unstructured":"Pradhan T.; Gupta O.; Singh G.; Monga V.; Aurora kinase inhibitors as potential anticancer agents: Recent advances. Eur J Med Chem  2021,221,113495","journal-title":"Eur J Med Chem"},{"key":"ref=197","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1093\/annonc\/mdq344","volume":"22","author":"Boss D.S.","year":"2011","unstructured":"Boss D.S.; Witteveen P.O.; van der Sar J.; Lolkema M.P.; Voest E.E.; Stockman P.K.; Ataman O.; Wilson D.; Das S.; Schellens J.H.; Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol  2011,22(2),431-437","journal-title":"Ann Oncol"},{"key":"ref=198","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00280-010-1318-9","volume":"67","author":"Traynor A.M.","year":"2011","unstructured":"Traynor A.M.; Hewitt M.; Liu G.; Flaherty K.T.; Clark J.; Freedman S.J.; Scott B.B.; Leighton A.M.; Watson P.A.; Zhao B.; O\u2019Dwyer P.J.; Wilding G.; Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol  2011,67(2),305-314","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref=199","doi-asserted-by":"publisher","first-page":"4106","DOI":"10.1073\/pnas.0608798104","volume":"104","author":"Manfredi M.G.","year":"2007","unstructured":"Manfredi M.G.; Ecsedy J.A.; Meetze K.A.; Balani S.K.; Burenkova O.; Chen W.; Galvin K.M.; Hoar K.M.; Huck J.J.; LeRoy P.J.; Ray E.T.; Sells T.B.; Stringer B.; Stroud S.G.; Vos T.J.; Weatherhead G.S.; Wysong D.R.; Zhang M.; Bolen J.B.; Claiborne C.F.; Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci USA  2007,104(10),4106-4111","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=200","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1182\/blood-2009-12-259523","volume":"115","author":"G\u00f6rg\u00fcn G.","year":"2010","unstructured":"G\u00f6rg\u00fcn G.; Calabrese E.; Hideshima T.; Ecsedy J.; Perrone G.; Mani M.; Ikeda H.; Bianchi G.; Hu Y.; Cirstea D.; Santo L.; Tai Y.T.; Nahar S.; Zheng M.; Bandi M.; Carrasco R.D.; Raje N.; Munshi N.; Richardson P.; Anderson K.C.; A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood  2010,115(25),5202-5213","journal-title":"Blood"},{"key":"ref=201","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1158\/1078-0432.CCR-05-1964","volume":"12","author":"Soncini C.","year":"2006","unstructured":"Soncini C.; Carpinelli P.; Gianellini L.; Fancelli D.; Vianello P.; Rusconi L.; Storici P.; Zugnoni P.; Pesenti E.; Croci V.; Ceruti R.; Giorgini M.L.; Cappella P.; Ballinari D.; Sola F.; Varasi M.; Bravo R.; Moll J.; PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity. Clin Cancer Res  2006,12(13),4080-4089","journal-title":"Clin Cancer Res"},{"key":"ref=202","first-page":"934","volume":"2009","author":"Benten D.","unstructured":"Benten D.; Keller G.; Quaas A.; Schrader J.; Gontarewicz A.; Balabanov S.; Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model. Neoplasia  ,2009(9),934","journal-title":"Neoplasia"},{"key":"ref=203","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1871524922666220404164405","volume":"22","author":"Joshi S.","year":"2022","unstructured":"Joshi S.; Dhingra A.K.; Chopra B.; Guarve K.; Bhateja D.; Therapeutic potential and clinical evidence of hesperidin as neuroprotective agent. Cent Nerv Syst Agents Med Chem  2022,22(1),5-14","journal-title":"Cent Nerv Syst Agents Med Chem"},{"key":"ref=204","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1159\/000258705","volume":"91","author":"Georgieva I.","year":"2010","unstructured":"Georgieva I.; Koychev D.; Wang Y.; Holstein J.; Hopfenm\u00fcller W.; Zeitz M.; Grabowski P.; ZM447439, a novel promising aurora kinase inhibitor, provokes antiproliferative and proapoptotic effects alone and in combination with bio- and chemotherapeutic agents in gastroenteropancreatic neuroendocrine tumor cell lines. Neuroendocrinology  2010,91(2),121-130","journal-title":"Neuroendocrinology"},{"key":"ref=205","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1158\/1535-7163.MCT-09-0765","volume":"9","author":"Dar A.A.","year":"2010","unstructured":"Dar A.A.; Goff L.W.; Majid S.; Berlin J.; El-Rifai W.; Aurora kinase inhibitors-rising stars in cancer therapeutics? Mol Cancer Ther  2010,9(2),268-278","journal-title":"Mol Cancer Ther"},{"key":"ref=206","doi-asserted-by":"publisher","author":"Chung M.S.","unstructured":"Chung M.S.; Han S.J.; Endometriosis-associated angiogenesis and anti-angiogenic therapy for endometriosis. Front. Global Women's Health.,  2022, 3, 856316","DOI":"10.3389\/fgwh.2022.856316"},{"key":"ref=207","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1158\/1535-7163.MCT-07-2156","volume":"6","author":"Chan F.","year":"2007","unstructured":"Chan F.; Sun C.; Perumal M.; Nguyen Q.D.; Bavetsias V.; McDonald E.; Martins V.; Wilsher N.E.; Raynaud F.I.; Valenti M.; Eccles S.; te Poele R.; Workman P.; Aboagye E.O.; Linardopoulos S.; Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther  2007,6(12),3147-3157","journal-title":"Mol Cancer Ther"},{"key":"ref=208","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1158\/1078-0432.CCR-14-1592","volume":"21","author":"Moreno L.","year":"2015","unstructured":"Moreno L.; Marshall L.V.; Pearson A.D.J.; Morland B.; Elliott M.; Campbell-Hewson Q.; . A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: A Cancer Research UK study.  Clin Cancer Res  2015,21(2),267-73","journal-title":"Clin Cancer Res"},{"key":"ref=209","first-page":"5729","volume":"68","author":"Joshi-Hangal R.","year":"2008","unstructured":"Joshi-Hangal R.; Tang C.; Sadikin S.; Inloes R.; Shi C.; Severson P.; Lamb J.; Bearss D.; Redkar S.; Kanekal S.; Pharmacokinetics of MP529, a selective Aurora A kinase inhibitor, in a novel subcutaneous delivery system . Exp Mol Med  2008,68(9_Supplement),5729","journal-title":"Exp Mol Med"},{"key":"ref=210","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1158\/1535-7163.MCT-08-0754","volume":"8","author":"VanderPorten E.C.","year":"2009","unstructured":"VanderPorten E.C.; Taverna P.; Hogan J.N.; Ballinger M.D.; Flanagan W.M.; Fucini R.V.; The Aurora kinase inhibitor SNS-314 shows broad therapeutic potential with chemotherapeutics and synergy with microtubule-targeted agents in a colon carcinoma model. Mol Cancer Ther  2009,8(4),930-939","journal-title":"Mol Cancer Ther"},{"key":"ref=211","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00432-009-0641-1","volume":"136","author":"McLaughlin J.","year":"2010","unstructured":"McLaughlin J.; Markovtsov V.; Li H.; Wong S.; Gelman M.; Zhu Y.; Franci C.; Lang D.W.; Pali E.; Lasaga J.; Low C.; Zhao F.; Chang B.; Gururaja T.L.; Xu W.; Baluom M.; Sweeny D.; Carroll D.; Sran A.; Thota S.; Parmer M.; Romane A.; Clemens G.; Grossbard E.; Qu K.; Jenkins Y.; Kinoshita T.; Taylor V.; Holland S.J.; Argade A.; Singh R.; Pine P.; Payan D.G.; Hitoshi Y.; Preclinical characterization of Aurora kinase inhibitor R763\/AS703569 identified through an image-based phenotypic screen. J Cancer Res Clin Oncol  2010,136(1),99-113","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref=212","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2012.07.020","volume":"49","author":"Matulonis U.A.","year":"2013","unstructured":"Matulonis U.A.; Lee J.; Lasonde B.; Tew W.P.; Yehwalashet A.; Matei D.; Behbakht K.; Grothusen J.; Fleming G.; Lee N.K.; Arnott J.; Bray M.R.; Fletcher G.; Brokx R.D.; Castonguay V.; Mackay H.; Sidor C.F.; Oza A.M.; ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer  2013,49(1),121-131","journal-title":"Eur J Cancer"},{"key":"ref=213","unstructured":"ClinicalTrials.gov. Study of XL228 in Subjects With Chronic Myeloid Leukemia or Philadelphia-Chromosome-Positive Acute Lymphocytic Leukemia - Full Text View - ClinicalTrials Available from:  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00464113(Accessed on: 2022 Aug 25)"},{"key":"ref=214","year":"2022","unstructured":"Clincosm. TTP607 Clinical Trials Available from:  https:\/\/www.clincosm.com\/drug\/TTP607(Acessed on: 2022 Aug 25)2022"},{"key":"ref=215","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1016\/j.ejca.2011.07.008","volume":"47","author":"Sch\u00f6ffski P.","year":"2011","unstructured":"Sch\u00f6ffski P.; Jones S.F.; Dumez H.; Infante J.R.; Van Mieghem E.; Fowst C.; Gerletti P.; Xu H.; Jakubczak J.L.; English P.A.; Pierce K.J.; Burris H.A.; Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the oral aurora kinase inhibitor PF-03814735 in advanced solid tumours. Eur J Cancer  2011,47(15),2256-2264","journal-title":"Eur J Cancer"},{"key":"ref=216","unstructured":"A phase I pharmacologic study of CYC116, an oral aurora kinase inhibitor, in patients with advanced solid tumors. Available from:  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00560716(Acessed on: 2022 Aug 25)."},{"key":"ref=217","doi-asserted-by":"crossref","first-page":"913","DOI":"10.3390\/microorganisms3040913","volume":"2015","author":"Vitetta L","year":"2015","unstructured":"Vitetta L; Hall S; Coulson S.; Metabolic interactions in the Gastrointestinal Tract (GIT): Host, commensal, probiotics, and bacteriophage influences. Microorganisms  2015,2015(4),913","journal-title":"Microorganisms"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230503124408","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/216476\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230503124408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T07:57:04Z","timestamp":1722412624000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/216476\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":217,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230503124408","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-11-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}